HLA-B*1502 Allele is Associated with a Cross-reactivity Pattern of Cutaneous Adverse Reactions to Antiepileptic Drugs

被引：10
作者：
Wang, J. [1 ]
Zhang, J. [2 ]
Wu, X. [1 ]
Yu, P. [1 ]
Hong, Z. [1 ]
机构：
[1] Fudan Univ, Dept Neurol, Huashan Hosp, Inst Neurol,State Key Lab Med Neurobiol,Shanghai, Shanghai 200040, Peoples R China
[2] Fudan Univ, Dept Radiol, Huashan Hosp, Shanghai Med Coll, Shanghai 200040, Peoples R China
来源：
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2012年 / 40卷 / 01期
关键词：
ANTIEPILEPTIC DRUGS (AEDS); ASIAN PATIENTS; EPILEPSY; HUMAN LEUCOCYTE ANTIGEN-B (HLA-B)*1502 ALLELE; CROSS REACTIVITY; CUTANEOUS ADVERSE DRUG REACTIONS (cADRs); STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CARBAMAZEPINE HYPERSENSITIVITY; HAN CHINESE; POPULATION; MARKER; RISK;
D O I：
10.1177/147323001204000140
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The US Food and Drug Administration has recommended genetic screening for the human leucocyte antigen-B (HLA-B)*1502 allele in patients of Asian ethnicity before starting carbamazepine therapy, to avoid the fatal adverse treatment-related events associated with this drug. The association between cross-reactivity to antiepileptic drugs (AEDs) and the HLA-B*1502 allele has been only rarely reported. Here, two cases of cross-reactivity to AEDs, where cutaneous adverse drug reactions (cADRs) developed in female Han Chinese patients with epilepsy who tested positive for the HLA-B*1502 allele, are described. If the genetic association could be confirmed in larger studies, the HLA-B*1502 allele should be tested for in any patient experiencing cADRs, to avoid cross-reactivity to AEDs.
引用
收藏
页码：377 / 382
页数：6
相关论文
共 18 条
[1]   HLA-B locus in Caucasian patients with carbamazepine hypersensitivity [J].
Alfirevic, Ana ;
Jorgensen, Andrea L. ;
Williamson, Paula R. ;
Chadwick, David W. ;
Park, B. Kevin ;
Pirmohamed, Munir .
PHARMACOGENOMICS, 2006, 7 (06) :813-818
[2]   Cross-reactivity pattern of rash from current aromatic antiepileptic drugs [J].
Alvestad, Sije ;
Lydersen, Stian ;
Brodtkorb, Eylert .
EPILEPSY RESEARCH, 2008, 80 (2-3) :194-200
[3]   Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population [J].
An, Dong-Mei ;
Wu, Xin-Tong ;
Hu, Fa-Yun ;
Yan, Bo ;
Stefan, Hermann ;
Zhou, Dong .
EPILEPSY RESEARCH, 2010, 92 (2-3) :226-230
[4]   Human leukocyte antigens and drug hypersensitivity [J].
Chung, Wen-Hung ;
Hung, Shuen-Lu ;
Chen, Yuan-Tsong .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (04) :317-323
[5]   A marker for Stevens-Johnson syndrome [J].
Chung, WH ;
Hung, SI ;
Hong, HS ;
Hsih, MS ;
Yang, LC ;
Ho, HC ;
Wu, JY ;
Chen, YT .
NATURE, 2004, 428 (6982) :486-486
[6]   Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations [J].
Ferrell, P. Brent, Jr. ;
McLeod, Howard L. .
PHARMACOGENOMICS, 2008, 9 (10) :1543-1546
[7]   Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population [J].
Hu, Fa-yun ;
Wu, Xin-tong ;
An, Dong-mei ;
Yan, Bo ;
Stefan, Hermann ;
Zhou, Dong .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2011, 20 (02) :160-162
[8]  
Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]
[9]   HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions [J].
Ikeda, Hiroko ;
Takahashi, Yukitoshi ;
Yamazaki, Etsuko ;
Fujiwara, Tateki ;
Kaniwa, Nahoko ;
Saito, Yoshiro ;
Aihara, Michiko ;
Kashiwagi, Mariko ;
Muramatsu, Masaaki .
EPILEPSIA, 2010, 51 (02) :297-300
[10]   High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients [J].
Kazeem, Gbenga R. ;
Cox, Charles ;
Aponte, Jennifer ;
Messenheimer, John ;
Brazell, Celia ;
Nelsen, Andrew C. ;
Nelson, Matthew R. ;
Foot, Elizabeth .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (09) :661-665
12